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Abstract Control of lipid levels is one of the most effective
strategies for cardiovascular (CV) event prevention. In fact,
many clinical trials have clearly demonstrated that low-
density lipoprotein cholesterol (LDL-C) lowering, primar-
ily with statins, reduces major CV events and mortality. The
evidence from these trials has been useful in designing the
cholesterol treatment guidelines, which are mainly aimed at
preventing and managing cardiovascular disease (CVD).
However, available data indicate that a large proportion of
patients fail to achieve lipid goals, and this is particularly
frequent in patients at high or very high CV risk. Further-
more, owing to side effects, a significant percentage of
patients cannot tolerate statin treatment. Hence, researchers
have focused their attention on novel LDL-C-lowering
agents that act via mechanisms distinct from that of statins.
Among the new compounds under investigation, the mon-
oclonal antibodies to proprotein convertase subtilisin/kexin
type 9 (PCSK9) seem particularly promising, having
recently been shown to be well tolerated and highly effec-
tive at lowering LDL-C, with a possible effect on the
occurrence of CV events. Currently, alirocumab is approved
by the US Food and Drug Administration (FDA) as an
adjunct to diet and maximally tolerated statin therapy for
use in adults with heterozygous familial hypercholes-
terolemia (FH) or those with atherosclerotic CV disease
who require additional LDL-C lowering; it has also been
recently approved by the European Medicines Agency
(EMA) for use in patients with heterozygous FH, non–fa-
milial hypercholesterolemia or mixed dyslipidemia in
whom statins are ineffective or not tolerated. Evolocumab is
approved by the FDA as an adjunct to diet and maximally
tolerated statins for adults with hetero- and homozygous FH
and those with atherosclerotic CV disease who require
additional lowering of LDL-C, and by the EMA in adults
with primary hypercholesterolemia or mixed dyslipidemia,
as an adjunct to diet, in combination with a statin or a statin
with other lipid lowering therapies in patients unable to
reach LDL-C goals with the maximum tolerated dose of a
statin; alone or in combination with other lipid lowering
therapies in patients who are statin-intolerant, or those for
whom a statin is contraindicated. Evolocumab is also
indicated in adults and adolescents aged 12 years and over
with homozygous familial hypercholesterolemia in combi-
nation with other lipid-lowering therapies.
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1 Introduction
Cardiovascular disease (CVD) remains the leading cause of
death and a major cause of disability in western countries,
and it is also becoming increasingly common in developing
countries [1, 2]. The causes of CVD are multifactorial;
cardiovascular (CV) risk is strongly influenced by lifestyle,
especially an unhealthy diet, tobacco use and sedentary
habits, which are modifiable [1, 2]. A relevant role is also
played by other modifiable risk factors, such as high blood
pressure, diabetes and dyslipidemias, and by non-
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modifiable factors like age and male gender [1, 2]. In the
last few decades preventive strategies based on lifestyle
changes and control of CV risk factors provided significant
benefits; in the MONICA project, which took place during
the 1980s and 1990s [3], the relationship between changes
in risk factor scores and CV event rates was substantial,
with the changes in risk factors explaining almost half the
variation in event rates.
Control of lipid levels is one of the most effective
strategies for CVD prevention. Epidemiologic data have
demonstrated the crucial role of dyslipidemia, especially
hypercholesterolemia, in the development of CVD [4]. It
is well understood that accumulation of cholesterol-rich
low density lipoproteins over time leads to formation of
lipid-laden foam cells and proliferation of atheroscle-
rotic lesions, increasing the risk of CVD [5]. Reduction
of cholesterol levels may be achieved by implementing
lifestyle changes, and use of pharmacological interven-
tions such as statins, bile acid sequestrants, nicotinic
acid and cholesterol absorption inhibitors. Available
evidence confirms that reducing plasma low-density
lipoprotein cholesterol (LDL-C) reduces CVD risk, and
it is generally accepted that the reduction of LDL-C
levels is of prime importance in the prevention of CVD;
most current guidelines on the management of dyslipi-
demia or the prevention of CVD identify LDL-C as a
primary treatment target [1, 6–9]. Many clinical trials
have clearly demonstrated that cholesterol lowering,
primarily with statins, reduces major vascular events and
mortality [10].
The data obtained in more than 25 years of clinical
trials have established statins as the preferred therapy for
the prevention and treatment of atherosclerotic CVD. Due
to their demonstrated efficacy and safety, they have
become first-line therapy when lipids are elevated despite
appropriate lifestyle changes. After the demonstration of
the favourable effect of statins on CV outcomes when
used in both primary and secondary prevention strategies
[11], subsequent findings suggested the possibility that
intensive treatment with statins and attainment of lower
LDL-C targets might lead to greater benefits [10]; more
recently, the results of the double-blind, randomized
IMPROVE-IT study indicated that simvastatin and eze-
timibe combination therapy improved overall cardiovas-
cular outcomes by significantly lowering median time-
weighted average LDL-C level (53.7 mg/dL) when com-
pared to simvastatin monotherapy (69.5 mg/dL;
p\ 0.001), thus adding further weight to the idea that
more intensive LDL-C-lowering results in better CV
outcomes [12]. Our aim is to present an overview of the
management of hypercholesterolemia, with a focus on
current unmet needs and the novel therapies currently
being investigated that may fill those gaps.
2 Achievement of Treatment Targets
The current European Society of Cardiology and European
Atherosclerosis Society (ESC/EAS) guidelines [9] recom-
mend treatment targets for dyslipidemia that are primarily
based on results from clinical trials; since in nearly all
lipid-lowering trials the LDL-C level has been used as an
indicator of response to therapy, the recommendations
centre on LDL-C. The ESC/EAS guidelines recommend
modulating the intensity of the preventive intervention
according to the total level of CV risk, where moderate risk
is defined as a calculated SCORE (Systematic Coronary
Risk Estimation) of C1 and\5 % at 10 years, high risk is
defined as a calculated 10-year SCORE of C5 and\10 %
and/or a markedly elevated single risk factor (e.g., familial
dyslipidemia, severe hypertension), and very high risk is
defined as documented CVD, previous myocardial infarc-
tion, acute coronary syndrome, coronary revascularisation,
ischaemic stroke, or peripheral arterial disease; and/or type
2 diabetes or patients with type 1 diabetes with target organ
damage; and/or a calculated 10-year SCORE of C10 %.
For LDL-C, these guidelines recommend a target of
\100 mg/dL in high risk patients (level of evidence: class
IIa, level A) and a target of\70 mg/dL for very high risk
patients (class I, level A); a level of less than 115 mg/dL is
suggested for patients at moderate risk (class IIa, level C)
[9]. Non-high-density lipoprotein cholesterol (non-HDL-C)
(which includes very low density lipoproteins, intermedi-
ate-density lipoproteins, lipoprotein (a) and other rem-
nants) and apolipoprotein B (apoB) have also been used as
secondary targets for the treatment of CVD [9].
Recent data further reinforce the concept that achieving
lower LDL-C targets may confer even greater benefits. A
recent meta-analysis on individual patient data from eight
randomized statin trials found that patients who achieve very
low LDL-C levels (\50 mg/dL) have a lower risk of CV
events than do those achieving moderately low levels
(Fig. 1) [13]. Of note, patients achieving an LDL-C level of
\50 mg/dL had a statistically significant decrease in the risk
of CV events even versus patients with an LDL-C level
between 75 and\100 mg/dL [adjusted hazard ratio (HR):
Fig. 1 Risk of major cardiovascular events versus LDL-C levels
Reproduced with permission from Boekholdt et al. [13]
218 E. Agabiti Rosei, M. Salvetti
0.81; 95 % confidence interval (CI): 0.70–0.95]. However,
the study also showed large inter-individual variability in the
reduction in levels of LDL-C, non-HDL-C, and apoB
achieved with fixed-dose statins; more than 40 % of patients
receiving high-dose statin therapy (defined as atorvastatin
80 mg or rosuvastatin 20 mg) did not achieve the LDL-C
target of\70 mg/dL, while 11.7 and 33.7 % did not achieve
non-HDL-C targets of\130 and\100 mg/dL, respectively,
and 14.7 and 35.7 % did not achieve apoB targets of\100
and\80 mg/dL, respectively [13]. The study underlines the
fact that a large proportion of patients fail to achieve the lipid
targets suggested by current guidelines and, at the same time,
seems to indicate that insufficient control of LDL-C levels in
these patients might expose them to an increased risk of CV
events. Inadequate control of lipid levels seems to be even
more common in everyday practice: the results of EURO-
ASPIRE IV [14], a cross-sectional study reporting data from
24 European countries, have shown that less than 20 % of
patients with known coronary artery disease attain the LDL-
C levels indicated by European guidelines. These results are
in accordance with earlier multinational surveys of sec-
ondary prevention practice conducted in Europe and in other
parts of the world [15–17].
It is therefore evident that attainment of lipid targets is
infrequent, both in everyday practice and in clinical trials,
even in very high risk patients in whom LDL-C should be
more aggressively reduced, such as those with severe pri-
mary hypercholesterolemia, including familial hyperc-
holesterolemia (FH; an autosomal dominant disorder
involving mutations primarily in the LDL receptor gene,
characterised by defective plasma LDL-C catabolism and
LDL-C levels of at least two times normal [18, 19]). As
recognized by current European guidelines, even with
maximum doses of lipid-lowering therapies, one cannot
expect to achieve optimal lipid levels (\70 mg/dL) in
patients with very high baseline LDL-C levels; the maxi-
mum reduction in LDL-C that can be achieved without
inducing side effects is therefore considered an accept-
able option [9]. In these patients, generally maximum doses
of atorvastatin (80 mg [20]) or rosuvastatin (40 mg [21])
are required, and combination therapy is often considered
[9]. Despite this, only a minority of these patients achieve
the suggested targets; in a large, cross-sectional study of
1249 patients with heterozygous FH (heFH) in the
Netherlands, only 21 % of patients achieved an LDL-C
target of\2.5 mmol/L (\100 mg/dL) [22].
3 Reasons for Unmet Needs
In addition to the aforementioned reasons, lack of attain-
ment of lipid targets may be explained by several other
factors. For example, non-adherence to cholesterol-
lowering medication is a significant clinical problem [23].
A study performed in Italy showed that the initial statin
prescription was not followed by another prescription in
47.5 % of newly-treated patients [24], confirming previous
results from a meta-analysis indicating that as many as
60 % of patients may stop their statin therapy within
6 months of treatment initiation [25].
The reasons for non-adherence are incompletely
understood. Among the possible explanations, the asymp-
tomatic nature of the disease is likely to play a role. In fact,
it has been demonstrated that patient perception of the
disease may influence adherence, and patients with a per-
sonal history of heart disease are more adherent to statin
therapy than patients with no personal history [23].
Side effects of treatment will certainly affect adherence.
A recognized side effect of statins is statin-myositis,
defined as muscle symptoms in association with a sub-
stantially elevated serum creatine kinase (CK) concentra-
tion; albeit serious, statin-associated myopathy is a rare
side effect, affecting 1 in 1000 to 1 in 10,000 people on
statin treatment [26]. In contrast, statin-associated muscle
symptoms (SAMS) in which CK concentrations are normal
or only slightly elevated, are much more common: data
from patient registries indicate a prevalence of 7–29 %
[27–31]. SAMS are likely to be one of the principal reasons
for the 75 % statin discontinuation rates seen within
2 years of treatment initiation, as well as a significant
contributor to statin non-adherence rates, therefore con-
tributing to the lack of control of cholesterol levels [26].
EAS recently published a consensus document which
presents an overview of current understanding of the
pathophysiology of SAMS, and provides guidance for
diagnosis and management of this condition [26]. The
panel proposed to identify the occurrence of SAMS via the
presence of typical statin-related myalgia (muscle pain/
aching), and the temporal relationship between the pres-
ence of SAMS and statin initiation, discontinuation and
statin re-exposure following discontinuation [26]. The use
of the maximum tolerated statin dose combined with non-
statin lipid-lowering therapies is recommended in patients
with SAMS and uncontrolled hypercholesterolemia [26].
Among these additional non-statin lipid-lowering thera-
pies, ezetimibe is proposed as a first-line drug, in view of
its ability to reduce LDL-C by 15–20 % with few side
effects [26, 32], and of the demonstration of a significant
effectiveness in reducing CV outcomes in the IMPROVE-
IT study, in which the addition of ezetimibe 10 mg to
simvastatin 40 mg significantly reduced the primary com-
posite CV end point versus simvastatin monotherapy
(Kaplan–Meier event rate at 7 years: 32.7 vs. 34.7 %; HR:
0.936; 95 % CI 0.89–0.99; p = 0.016) [12]. The EAS
panel concluded that with proper recognition of SAMS and
adherence to a structured work-up, patients with clinically
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relevant SAMS can be offered treatment regimens that will
address their CVD risk in a satisfactory manner.
4 Novel Therapies
Given current unmet needs, there is a major requirement
for additional therapeutic options for lipid lowering.
Therefore, researchers have focused their attention on the
development of novel therapies that address the limitations
of currently available treatments for hypercholesterolemia
and that might have good tolerability as well as the
potential to lower serum LDL-C levels below those
achievable with statin therapy alone.
4.1 Proprotein Convertase Subtilisin/Kexin Type 9
(PCSK9)
In 2003, Seidah et al. identified proprotein convertase
subtilisin/kexin type 9 (PCSK9), a secreted 692-amino acid
protein belonging to the proprotein convertase family that
post-transcriptionally promotes a reduction in LDL recep-
tor levels [33]. Secreted from the liver, circulating PCSK9
binds to the LDL receptor and is subsequently internalized
with the receptor, promoting its cellular degradation ( 2).
In the same year, Abifadel and coworkers [34] identified
gain of function (GOF) mutations of PCSK9 as a third
cause of FH, after exclusion of mutations in the LDL
receptor apoB. Subsequently, in 2004 and 2005, other
PCSK9 GOF mutations were described in FH patients from
the UK, USA and Norway [18, 19, 35]. GOF mutations are
rare, accounting for a minority of cases of FH; available
data indicate that these mutations are not only associated
with high cholesterol levels, but also with a greater
atherosclerotic burden [36], similar to what is observed
with the more traditional mutations in the LDL receptor
and apoB that lead to FH. Interestingly, several loss-of-
function (LOF) mutations in PCSK9 have been found
associated with lower plasma LDL-C and lower prevalence
of coronary artery disease. Furthermore, the longitudinal
data of the atherosclerosis risk in communities (ARIC)
study [37] have shown that compared with non-carriers, the
presence of the LOF mutations Y142X and C679X in
African Americans was associated with a 28 and 88 %
reduction in LDL-C and risk of CHD, respectively. In the
same study, the R46L mutation in Caucasians was associ-
ated with a reduction in LDL-C of 15 %, and a reduction in
the risk of CHD of 47 %, versus non-carriers [37]. In a
meta-analysis published in 2010 [38], 46L allele carriers
had a 12 % reduction in LDL-C and a 28 % reduction in
risk of ischemic heart disease. Taken together, these results
suggest that inhibition of PCSK9 may be a possible
treatment option for patients with uncontrolled LDL-C and
high CV risk.
4.2 Alirocumab
Alirocumab (formerly REGN727/SAR236553) is a PCSK9
inhibitor which has been approved by the US Food and
Drug Administration (FDA) for use as an adjunct to diet
and maximally tolerated statin therapy in adult patients
with heterozygous FH or those with atherosclerotic CVD
who require additional lowering of LDL-C. It is a fully
human monoclonal antibody against PCSK9 administered
by subcutaneous injection, and it blocks the ability of
PCSK9 to bind surface LDL receptor [39]. The efficacy of
alirocumab in reducing LDL-C has been investigated in
several studies. Stein and co-workers published the first
clear demonstration of the LDL-C-lowering effect of
antibodies to PCSK9 in humans in a phase I, multilevel,
single ascending dose study in which 0.3, 1, 3, 6 and
12 mg/kg doses of alirocumab were administered intra-
venously in healthy subjects [39]. A significant, dose
dependent reduction in LDL-C was observed (reduction
ranging from -28 to -65 % vs placebo), with a plateau
effect at 3, 6 and 12 mg/kg, suggesting system saturation
(i.e., complete binding of circulating PCSK9). The duration
of LDL-C lowering was dose-dependent, with prolonged
reductions (up to 64 days) seen with the higher doses, and a
relationship between the reduction in free PCSK9 levels
and the decrease in LDL-C levels following alirocumab
administration was seen [39]. The results of a phase I study
in which alirocumab was administered by subcutaneous
injection (at doses of 50, 100, 150 or 250 mg) in healthy
volunteers was also described [39]; the study demonstrated
the efficacy of alirocumab in reducing LDL-C (reduction
ranging from -32.5 to -45.7 % vs placebo). Both studies
indicated that no additional lowering of LDL-C occurs
once all of the available plasma PCSK9 is bound to alir-
ocumab. However, higher doses of alirocumab prolong the
duration of the LDL-C-lowering effect, as newly released
PCSK9 binds to the excess drug. Stein et al. also described
the results of treatment with multiple subcutaneous doses
of alirocumab in adults with heFH (n = 21), and in patients
with non-familial hypercholesterolemia (n = 30), all of
whom were receiving treatment with atorvastatin, and in
patients with non-familial hypercholesterolemia treated
with modified diet alone (n = 10) [39]. No difference in
the percent reduction of LDL-C or in the duration of the
reduction was observed between patients with or without
FH, suggesting that PCSK9 inhibition was able to over-
come the adverse functional effects of the genetic mutation
in the LDL receptor present in FH. Similarly, the percent
reduction in LDL-C was not different whether or not
patients were taking atorvastatin [39]. In a pooled analysis
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(placebo vs. alirocumab), the mean LDL-C reductions from
baseline in patients receiving alirocumab 50, 100, and
150 mg were 39.2, 53.7, and 61.0 %, respectively, versus
placebo (p\ 0.001 for all). However, the duration of LDL-
C reduction was shorter in patients receiving atorvastatin,
which may be a result of statin administration enhancing
PCSK9 transcription and increasing circulating PCSK9
levels. Of note, alirocumab was generally well tolerated.
Subsequent phase II studies confirmed the promising
results obtained with alirocumab in the aforementioned
phase I studies. A phase II study was carried out in 183
hypercholesterolemic patients with LDL-C [100 mg/dL
despite stable atorvastatin therapy [40] treated with sub-
cutaneous alirocumab 50, 100, or 150 mg Q2W, or with
200 or 300 mg every 4 weeks (Q4W), alternating with
placebo for a total treatment period of 12 weeks. Reduc-
tions in LDL-C from baseline ranged from 40 to 72 and 43
to 48 % in patients treated Q2W and Q4W, respectively. In
this study, alirocumab was generally well tolerated, but one
patient experienced leukocytoclastic vasculitis. Although
2 PCSK9-mediated degradation of the LDL receptor. The secreted
PCSK9 binds the epidermal growth factor-like repeat A domain of the
LDL receptor present on the plasma membrane of hepatocytes. The
complex undergoes clathrin-mediated endocytosis and is then
escorted to lysosomes for degradation, in contrast to the physiological
recycling of the LDL receptor to the plasma membrane, after binding
the circulating LDL particle. The therapeutic approaches that inhibit
circulating PCSK9 are highlighted in red boxes Reproduced with
permission from Norata et al. [68]
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the exact cause of the leukocytoclastic vasculitis in this
subject cannot be determined, the investigators considered
it related to study drug administration [40]. Stein and co-
workers reported the results of a phase II, randomized,
multicentre, placebo controlled study in which 77 patients
with FH treated with statins with or without ezetimibe and
with LDL-C levels[100 mg/dL underwent treatment with
alirocumab 150, 200, or 300 mg Q4W or alirocumab
150 mg Q2W, or placebo Q2W [41]. LDL-C levels were
reduced by 28.87, 31.54, and 42.53 % in the alirocumab
150, 200, and 300 mg Q4W groups, respectively, and by
67.90 % in the alirocumab 150 mg Q2W group (versus
10.65 % in placebo recipients). While Q4W dosing
achieved similar reductions to the 150 mg Q2W dose at
2 weeks, the LDL-C reduction was not fully maintained
over the full 4 week-period [41]. In a subsequent phase II
study [42] 92 patients who had LDL-C levels of C100 mg/
dL after treatment with 10 mg of atorvastatin for at least
7 weeks were randomly assigned to receive 8 weeks of
treatment with atorvastatin 80 mg/day plus subcutaneous
alirocumab 150 mg Q2W, atorvastatin 10 mg/day plus
subcutaneous alirocumab 150 mg Q2W, or atorvastatin
80 mg/day plus placebo Q2W. As expected, the addition of
alirocumab to atorvastatin was more effective at reducing
LDL-C levels at 8 weeks than simply increasing the dosage
of atorvastatin ( 3).
The phase III clinical trial program for alirocumab is
named ‘‘ODYSSEY’’, and comprises 14 global phase 3
trials, including more than 23,500 patients across more
than 2000 study centres in more than 40 countries around
the world (Fig. 4). These trials primarily focused on three
groups of patients with uncontrolled hypercholesterolemia
on existing therapies: those with heFH, those at high CV
risk, and those with statin intolerance. The majority of
patients enrolled in the ODYSSEY trials were at high CV
risk and were receiving maximally tolerated doses of
statins.
The results of the ODYSSEY ALTERNATIVE,
ODYSSEY HIGH FH, ODYSSEY COMBO I and
ODYSSEY OPTIONS I and II have been published
[43–46]; ODYSSEY CHOICE I and II studies are only
available as conference abstracts at the time of writing;
results from these studies were presented at the Interna-
tional Symposium on Atherosclerosis in May 2015.
ODYSSEY ALTERNATIVE enrolled 361 patients with
documented statin intolerance, with LDL-C C70 mg/dL
and very high CV risk or LDL-C C100 mg/dL and mod-
erate/high CV risk; a single-blind subcutaneous and oral
placebo was given to the patients for four weeks to check
for placebo induced muscle-related adverse events. Patients
reporting adverse events were withdrawn from the study
and the others were randomized (2:2:1 ratio) to alirocumab
75 mg self-administered via single 1 mL prefilled pen
every 2 weeks or ezetimibe 10 mg/day or atorvastatin
20 mg/day (statin re-challenge), for 24 weeks. Patients
received alirocumab 75 mg Q2W with the possibility of
uptitration to alirocumab 150 mg Q2W at week 12
depending on CV risk and if LDL-C goals were not
achieved by week 8. The primary efficacy analysis showed
that after 24 weeks, alirocumab treatment resulted in a
significantly greater LDL-C reduction from baseline than
ezetimibe treatment. Adverse events were generally similar
between groups; skeletal muscle-related treatment-emer-
gent adverse events occurred significantly less frequently
in the alirocumab group versus the atorvastatin group
(p = 0.042). ODYSSEY HIGH FH compared the LDL-C-
lowering efficacy and safety of subcutaneous alirocumab
and placebo in heFH patients with LDL-C C160 mg/dL
despite maximally tolerated statin with or without other
lipid-lowering treatments. Alirocumab 150 mg Q2W pro-
duced significantly greater LDL-C reductions from base-
line versus placebo at week 24, and had an excellent safety
profile. In ODYSSEY COMBO I, 316 patients with
hypercholesterolemia and documented CVD (established
CHD or CHD risk equivalents) who were receiving max-
imally tolerated doses of statins with or without other lipid-
lowering therapies were randomised to receive either alir-
ocumab or placebo; if patients had not achieved LDL-C
goals by week 8, there was an option to increase alir-
ocumab to 150 mg Q2W. Patients receiving alirocumab
had significantly greater reductions from baseline in LDL-
C compared with placebo recipients (p\ 0.0001), while
treatment-emergent adverse events were similar between
groups. ODYSSEY OPTIONS I and II investigated the
efficacy and safety of alirocumab as add-on therapy to
atorvastatin versus ezetimibe plus atorvastatin, the dou-
bling of the atorvastatin dose, or switching from atorvas-
tatin to rosuvastatin in high CV risk patients with
hypercholesterolemia who were not at goal despite existing
therapy with non-maximal doses of atorvastatin. At
24 weeks, the alirocumab groups experienced greater
LDL-C reductions compared with other treatment options;
safety and tolerability was comparable across all groups.
The ODYSSEY CHOICE I study enrolled patients with
hypercholesterolemia who had: a moderate to very high
CV risk and were receiving maximally-tolerated statin
doses; a moderate CV risk and were not receiving statins;
or a moderate to very high CV risk and statin intolerance.
Patients received either alirocumab 300 mg Q4W, alir-
ocumab 75 mg Q2W, or placebo; patients who had not
achieved LDL-C goals at week 8 received alirocumab
150 mg Q2W from week 12. After 24 weeks of treatment,
patients receiving alirocumab 300 mg Q4W had signifi-
cantly greater decreases from baseline in LDL-C versus
placebo recipients, regardless of whether patients were
receiving statin therapy (p\ 0.0001). Adverse events
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occurred at a similar rate in the placebo and alirocumab
300 mg groups; there was a higher rate of injection site
reactions in patients receiving alirocumab 300 mg Q4W
than placebo. The CHOICE II study included patients with
hypercholesterolemia who were receiving fenofibrate,
ezetimibe or diet alone and who had a moderate to very
high CV risk plus SAMS, or a moderate CV risk without
SAMS. Patients received either alirocumab 150 mg Q4W,
alirocumab 75 mg Q2W, or placebo; patients who had not
achieved LDL-C goals at week 8, or whose LDL-C
reduction was\30 % from baseline, received alirocumab
150 mg Q2W from week 12. At week 24, alirocumab
150 mg Q4W recipients had significantly greater LDL-C
reductions from baseline than placebo recipients
(p\ 0.0001).
The primary results of the ODYSSEY FH I and II,
ODYSSEY MONO, ODYSSEY COMBO II, and ODYS-
SEY LONG TERM have been fully published [47–50]. In
the ODYSSEY FH I and II studies, 735 heFH patients
treated with a maximally tolerated statin dose with or
without other lipid-lowering therapies with LDL-C
C70 mg/dL (plus history of CVD) or C100 mg/dL (plus
no history of CVD) were randomized to subcutaneous
alirocumab 75 mg Q2W or to placebo; the dose was
increased to 150 mg Q2W if the patient’s LDL-C level
remained C70 mg/dL at week 8. Alirocumab produced
significantly greater LDL-C reductions versus placebo at
week 24. Safety and tolerability were generally compara-
ble in the alirocumab and placebo groups. ODYSSEY
MONO investigated the use of alirocumab as monotherapy
[49]; a total of 103 patients were randomly assigned to an
initial dose of alirocumab 75 mg Q2W (with the possibility
of uptitration at 12 weeks if LDL-C level remained
C70 mg/dL at week 8) or ezetimibe 10 mg once daily.
After 24 weeks, the alirocumab group showed a signifi-
cantly greater least-squares mean reduction in LDL-C than
ezetimibe (47.2 % vs. 15.6 %; p\ 0.0001). Adverse
events were similar between the two groups. ODYSSEY
COMBO II compared the efficacy and safety of alir-
ocumab versus ezetimibe in 720 patients with high CV risk
and elevated LDL-C despite maximal doses of statins
(LDL-C C70 mg/dL plus history of CVD, or LDL-C
C100 mg/dL with no history of CVD) [47]. Patients were
randomized to subcutaneous alirocumab 75 mg Q2W (plus
oral placebo) or oral ezetimibe 10 mg/day (plus subcuta-
neous placebo) on a background of stable statin therapy,
with an option to uptitrate alirocumab to 150 mg Q2W at
week 12 in patients who were not at goal at week 8. The
primary efficacy analysis showed that at 24 weeks, alir-
ocumab recipients had a significantly greater reduction
Fig. 3 Mean percent change from baseline in LDL-C levels in patients atorvastatin with or without alirocumab. Reproduced with permission
from Roth et al. [42]
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from baseline in LDL-C than ezetimibe recipients
(p\ 0.0001; Fig. 5). Alirocumab was generally well tol-
erated, with no evidence of an excess of treatment-emer-
gent adverse events.
In the double-blind, randomized, placebo controlled
ODYSSEY LONG TERM trial, 2341 patients with
heterozygous FH with or without documented CVD or
patients with hypercholesterolemia and documented CVD
and LDL-C levels C70 mg/dL despite receiving the max-
imum tolerated doses of statins with or without other lipid-
lowering therapy, were randomly assigned subcutaneous
alirocumab 150 mg or placebo Q2W for 78 weeks. At
week 24, the difference between the alirocumab and pla-
cebo groups in the mean percentage change from baseline
in LDL-C levels was significant (p\ 0.001); the treatment
effect remained consistent up to 78 weeks (Fig. 6). The
percentage of patients with any adverse event was com-
parable between the two study groups. Interestingly, in a
post-hoc analysis, the rate of major adverse CV events
(death from coronary heart disease, nonfatal myocardial
infarction, fatal or nonfatal ischemic stroke, or unsta-
ble angina requiring hospitalization) was lower with
Fig. 4 The ODYSSEY clinical trial program. CV cardiovascular, FH
familial hypercholesterolemia, HC hypercholesterolemia, HeFH
heterozygous familial hypercholesterolemia, LDL-C low density
lipoprotein cholesterol, LMT lipid modifying therapy. Asterisk For
the ODYSSEY COMBO II other LMT not allowed at entry
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alirocumab than with placebo (1.7 vs. 3.3 %; HR: 0.52;
95 % CI 0.31–0.90; p = 0.02).
Undoubtedly, the results of the ODYSSEY LONG
TERM study are of great interest. The trial confirmed, in a
large population with high CV risk, that treatment with
alirocumab in patients already taking statins is well toler-
ated, and that it provides a reduction in LDL-C of more
than 60 %, which might translate into a*50 % decrease in
CV events. Of course, this last finding requires confirma-
tion, in view of the relatively small number of CV events
observed in the trial, the post hoc nature of the analysis,
and the relatively short duration of the observation period.
However, the ODYSSEY results as a whole give some
insights regarding the possible use of alirocumab not only
in patients with FH, but also in the large proportion of
hypercholesterolemic patients at high CV risk that fail to
reach appropriate lipid targets on statin therapy.
This issue is being formally tested by the ongoing phase
III ODYSSEY Outcomes trial (ClinicalTrials.gov number:
NCT01663402), that will test the hypothesis that alir-
ocumab, compared with subcutaneous placebo, reduces CV
morbidity and mortality in patients with recent acute
coronary syndrome and lipid levels that remain above
target despite intensive atorvastatin or rosuvastatin therapy
(or the maximally tolerated dose) [51]. Planned enrolment
is 18,000 patients who will be randomized to receive
alirocumab 75 mg Q2W, by subcutaneous injection or
matching placebo, with the option to uptitrate to alir-
ocumab 150 mg Q2W after 1 month, if LDL-C levels
remain C50 mg/dL; the protocol also includes the option to
downtitrate from alirocumab 150 mg Q2W to 75 mg Q2W
in patients who have two consecutive LDL-C levels of
\25 mg/dL. The primary efficacy endpoint is the com-
posite of: time to first occurrence of death from coronary
heart disease; nonfatal acute myocardial infarction; fatal or
nonfatal ischemic stroke; or unstable angina requiring
hospitalization. The trial will continue until 1613 primary
end point events have occurred; follow up is expected to be
a minimum of 2 years for each subject.
4.3 Evolocumab
Evolocumab is a monoclonal antibody against PCSK9
which is approved for use in the US as an adjunct to diet
and maximally tolerated statin therapy for the treatment of
adults with HeFH, homozygous FH (HoFH) or clinical
atherosclerotic CVD, who require additional lowering of
LDL-C [52]. In Europe, evolocumab is approved for the
Fig. 5 Reduction in LDL-C levels over time in the intent-to-treat population of ODYSSEY COMBO. Reproduced with permission from Cannon
et al. [47]
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs 225
treatment of adults with primary hypercholesterolemia
(heterozygous familial and non-familial) or mixed dys-
lipidemia, as an adjunct to diet either in combination with a
statin or a statin with other lipid lowering therapies in
patients unable to reach LDL-C goals with the maximum
tolerated dose of a statin, or alone or in combination with
other lipid-lowering therapies in patients who are statin-
intolerant, or those for whom a statin is contraindicated. It
is also indicated in adults and adolescents aged 12 years
and over with HoFH in combination with other lipid-low-
ering therapies [53]. After the positive results of the phase I
studies, in which the subcutaneous administration of evo-
locumab led to consistent reductions in LDL-C, subsequent
phase II studies further confirmed the efficacy and safety of
the compound. The phase II LAPLACE–TIMI 57 study
[54] tested multiple doses of the drug (70, 105 or 140 mg
Q2W and 280, 350 or 420 mg Q4 W) versus matching
placebo administered Q2W or Q4W in 631 patients already
on treatment with a statin with or without ezetimibe and
with LDL-C C85 mg/dL. At week 12, mean LDL-C con-
centrations were reduced in a dose-dependent manner by
evolocumab Q2W (41.8–66.1 %; p\ 0.0001 vs. placebo)
and evolocumab Q4W (41.8–50.3 %; p\ 0.0001 vs. pla-
cebo). Treatment-related adverse events were similar in the
evolocumab and placebo groups (8 vs 7 %) and none were
severe. The efficacy and safety of the compound were
confirmed by the results of the MENDEL study, which
compared evolocumab with ezetimibe or placebo in 406
patients with hypercholesterolemia not receiving concur-
rent lipid-lowering treatment [55]. Similarly, the drug led
to significant reductions in lipid levels in the RUTHER-
FORD study, in 167 patients with heFH with LDL-C
C100 mg/dL despite statin therapy with or without eze-
timibe [56], and in the GAUSS study, in 160 statin intol-
erant patients (defined as those with an inability to tolerate
C1 statin at any dose, or a dose above weekly maximums
of statins due to intolerable myalgia or myopathy, who
have an improvement in or resolution of symptoms when
statins are discontinued) [57]. These studies confirmed a
favourable safety profile of the drug.
A number of phase III trials have investigated or are
investigating the efficacy and safety profile of evolocumab
in various subsets of patients. In the LAPLACE-2 trial, the
compound was effective and safe when administered with
either moderate- or high-intensity statin therapy [58], while
in RUTHERFORD-2, in patients with heFH and LDL-C
level C100 mg/dL despite statin therapy, the drug proved
to be safe and efficacious in lowering lipid levels [59].
Three phase III trials, MENDEL 2, GAUSS 2 and DES-
CARTES 2, have been published in 2014, and demon-
strated consistent reductions in LDL-C in different subsets
of patients, including patients with Framingham risk scores
B10 % and LDL-C levels C100 and \190 mg/dL [60],
patients with statin intolerance [61], and in patients with
Fig. 6 Reduction in LDL-C levels over time in the intent-to-treat population of ODYSSEY LONG TERM. Reproduced with permission from
Robinson et al. [48]
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LDL-C level [75 mg/dL despite lipid-lowering therapy
with atorvastatin with or without ezetimibe [62]. In these
three studies evolocumab led to a reduction in LDL-C from
baseline of between 50 and 60 %.
The OSLER-1 and OSLER-2 open-label trials included
4465 patients with various degrees of CV risk who were
randomly assigned to receive either evolocumab 140 mg
Q2W or 420 mg Q4W plus standard therapy, or standard
therapy alone [63]. Versus standard therapy alone, evolo-
cumab reduced LDL-C levels by 61 % (95 % CI 59–63;
p\ 0.001), and this reduction was maintained at 48 weeks
(58.4 %; p\ 0.001). The rate of adverse events was low,
with no difference between groups. Interestingly, an
exploratory analysis showed that the rate of CV events at
1 year was reduced with evolocumab versus standard
therapy [0.95 vs. 2.18 %; HR (evolocumab group): 0.47;
95 % CI 0.28–0.78; p = 0.003]. These interesting results
require confirmation in larger studies specifically designed
for such endpoints, such as the ongoing FOURIER study
(ClinicalTrials.gov number: NCT01764633), which is a
randomized, placebo-controlled trial currently recruiting a
planned 27,500 high-risk patients with CVD receiving
background statin therapy which will test the effect of
evolocumab versus placebo on major CVD events.
4.4 Bococizumab
Bococizumab is a humanized monoclonal antibody against
PCSK9 which is in an earlier phase of development com-
pared with alirocumab and evolocumab. The results of
phase II studies have been presented in abstract form and
seem to indicate that the compound is effective and gen-
erally well tolerated. In two studies presented at the AHA
Scientific Sessions in 2012, substantial LDL-C lowering
was observed in hypercholesterolemic subjects treated with
the compound (single intravenous and subcutaneous
doses), both as monotherapy and when added to atorvas-
tatin therapy. The drug was well-tolerated.
To date the only phase II study published in extenso is a
dose ranging trial [64] in which subjects with LDL-C levels
C80 mg/dL on stable statin therapy were randomized to
Q14 days of subcutaneous placebo or bococizumab 50,
100, or 150 mg or Q28 days of subcutaneous placebo or
bococizumab 200 or 300 mg. When results were adjusted
for placebo, mean decreases from baseline in LDL-C ran-
ged from 35.0 to 53.1 % in patients receiving bococizumab
for 14 days, and from 27.0 to 41.1 % in patients receiving
28 days of bococizumab therapy. As observed in trials with
other PCSKS9 monoclonal antibodies, the percentage of
subjects reporting adverse events or serious adverse events
was similar across placebo and bococizumab treatment
groups; only 7 subjects (2 %) discontinued treatment
because of treatment-related adverse events.
The ongoing SPIRE program, which includes 5 phase III
trials, will further evaluate the efficacy and safety of
bococizumab in various subsets of patients; the results of
these studies are expected in 2016 and 2017.
4.5 Lomitapide
Lomitapide inhibits the microsomal triglyceride transport
protein (MTP), a key protein in the assembly and secretion
of apoB-containing lipoproteins in the liver and intestine
[65]. Inhibiting MTP leads to reduced levels of these
lipoproteins in the circulation. The efficacy and safety of
oral lomitapide has been evaluated in three small clinical
studies [65, 66]. The drug was approved in 2012 by the US
FDA and in 2013 by the European Medicines Agency for
patients with homozygous FH. The possible relevant liver
toxicity seen represents the main limitation of the drug;
also other gastrointestinal side effects have been described
(diarrhoea, nausea and vomiting) [65, 66].
4.6 Mipomersen
Mipomersen is an antisense oligonucleotide complemen-
tary to the coding region for human apolipoprotein B
messenger RNA (mRNA) [65]. Through direct binding to
apoB mRNA, mipomersen inhibits its production. The
effectiveness of mipomersen 400 mg administered subcu-
taneously once weekly has been tested in relatively small
studies in which the reduction in LDL-C ranged between
25 and 40 % [65, 67]. In these studies, the most common
adverse events have been injection site reactions (76 % of
patients), flu-like symptoms (*30 %, typically appearing
2 days after injection), and persistent increases in serum
alanine aminotransferase levels more than three times the
upper limit of normal (*10 %) [65, 67].
A field of ongoing research is that which is aiming to
increase HDL-C by increasing the activity of apolipopro-
tein A-I. These include infusions of recombinant HDL-C or
apolipoprotein A-I Milano, mimetic peptides and oral small
molecules [11].
5 Conclusion
Control of lipid levels is one of the most effective strategies
for CVD prevention. More than 25 years of clinical trial
data have clearly demonstrated that LDL-C lowering, pri-
marily with statins, reduces major CV events and mortality.
However, data from clinical trials and surveys clearly
indicate that a large proportion of patients fail to achieve
lipid goals, and this is frequent in patients at high or very
high CV risk, possibly leading to a high economic and
social burden.
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The development of novel lipid-lowering agents with
different mechanisms of action versus existing therapies
represents an appealing option for the treatment of patients
who fail to achieve lipid targets. In particular, a few years
after the discovery of rare PCSK9 mutations that may
strongly influence lipid profile and affect CV risk, PCSK9
inhibitors are being recognized as promising therapeutic
options for the treatment of hypercholesterolemia, in view
of their tolerability and efficacy in lowering LDL-C and
data suggesting a possible positive trend in CV outcomes
with the use of PCKS9 inhibitors in the treatment of
hypercholesterolemia. If the promising results obtained so
far with monoclonal antibodies against PCKS9 are con-
firmed by the ongoing large phase III outcomes studies,
clinicians will be provided with a new powerful tool for
lipid-level reduction and an optimal way to control CV
risk.
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